Christopher Derenzo, MD
Enriched profileAssociate Member, St. Jude Faculty · St. Jude Children's Research Hospital
Christopher Derenzo is Associate Member, St. Jude Faculty at St. Jude Children's Research Hospital. OpenAlex indexes 59 publications with 1,663 citations (h-index 18); ClinicalTrials.gov lists 1 registered study with this person as an investigator.
Data verified 4 Nov 2026
Overview
Updated 4 Nov 2026
Christopher DeRenzo, M.D., is Associate Member, St. Jude Faculty at St. Jude Children's Research Hospital. The public record shows 59 publications with 1,663 citations (h-index 18), centered on CAR-T cell therapy research, Cancer Immunotherapy and Biomarkers, Glioma Diagnosis and Treatment. It also documents an investigator role on 1 registered clinical trials, 1 NIH-funded awards (2022–2025).
- Top research focus: CAR-T cell therapy research
- 1 registered trials on ClinicalTrials.gov
Generated from the cited public record · current as of 4 Nov 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Publications indexed by OpenAlex, matched via ORCID. 9 in PubMed. Counts exclude supporting files.
Citations across these publications.
H-index from these publications. i10-index 24.
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 4 Nov 2026
Listed as an investigator on 1 registered study on ClinicalTrials.gov. The most recent:
- Loc3CAR: Locoregional Delivery of B7-H3-CAR T Cells for Pediatric Patients With Primary CNS Tumors
Sponsor: St. Jude Children's Research Hospital
Industry payments
No payments involving this person were reported to CMS in program years 2021–2024. Why? →
NIH funding
Updated 4 Nov 2026
1 NIH research award on record, funded 2022–2025 per NIH RePORTER. The latest:
- Enhancing B7-H3-CAR T cell therapy for pediatric solid tumors
St. Jude Children'S Research Hospital
FY2025$754,519R01CA262589 - Enhancing B7-H3-CAR T cell therapy for pediatric solid tumors
St. Jude Children'S Research Hospital
FY2024$716,793R01CA262589 - Enhancing B7-H3-CAR T cell therapy for pediatric solid tumors
St. Jude Children'S Research Hospital
FY2023$719,445R01CA262589
Congress activity
Updated 4 Nov 2026
20 congress contributions (2010–2026) across AACR, ASCO, ENDO, IMMUNOLOGY (AAI Annual Meeting), SITC, SNO per OpenAlex. The most recent:
- Single-cell profiling of CSF immune dynamics following intracranial B7-H3 CAR T cell therapy for pediatric brain tumors 2254484
IMMUNOLOGY (AAI Annual Meeting)
IMMUNOLOGY (AAI Annual Meeting)2026Co-author - TIRTL-sequencing to interrogate the clonal repertoire of CARpos and CARneg TILs post CAR T-cell therapy for pediatric solid tumors 2259261
IMMUNOLOGY (AAI Annual Meeting)
IMMUNOLOGY (AAI Annual Meeting)2026Co-author - Epigenetic regulators of clonal hematopoiesis control CD8 T cell stemness during immunotherapy 2034
IMMUNOLOGY (AAI Annual Meeting)
IMMUNOLOGY (AAI Annual Meeting)2025Co-author
Published abstracts are attributed via the same ORCID-disambiguated authorship as publications, so each is DOI-verified. Podium roles (invited talks, session chairs) and oral/poster type are added as program data is confirmed.
Publications
None on file yet. We only list publications we can confidently match to this person. Why? →
Most-cited works
by citation count (OpenAlex)- 01CAR T Cell Therapy for Solid Tumors: Bright Future or Dark Reality?Article380 citations2020
- 02
- 03cBAF complex components and MYC cooperate early in CD8+ T cell fateArticle167 citations2022
- 04
- 05Autologous HER2-specific CAR T cells after lymphodepletion for advanced sarcoma: a phase 1 trialArticle110 citations2024
Network
Updated 4 Nov 2026
The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.
Online presence
Updated 4 Nov 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Owned accounts
public accounts run by this person- Doximity
doximity.com/pub/christopher-derenzo-md
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →doximity.com ↗
Mentions by others
where others cite or feature them- Other
stjude.org/people/d/christopher-derenzo.html
verifiedCorroborated by FindMyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →stjude.org ↗
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Background & recognition
Updated 4 Nov 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- MD
Rutgers Robert Wood Johnson Medical School
verifiedCorroborated by FindMyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →stjude.org ↗ - MBA
Rutgers Business School
verifiedCorroborated by FindMyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →stjude.org ↗
Media & interviews
press, podcasts and appearances- Disrupting Asxl1 gene prevents T-cell exhaustion
improving immunotherapy (10/10/2024), listed on St. Jude profile
2024verifiedCorroborated by FindMyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →stjude.org ↗ - Improved chemokine homing enhances CAR T-cell therapy for osteosarcoma (08/05/2024)
listed on St. Jude profile
2024verifiedCorroborated by FindMyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →stjude.org ↗ - Speaker
webinar "Optimizing B7-H3-CAR-T Cells for Targeting Solid Tumors" (Agilent, Breakthroughs in Immuno-Oncology series; date not stated)
verifiedCorroborated by FindMyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →explore.agilent.com ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
Amar Gajjar, MD
St. Jude Children's Research Hospital
Thomas Merchant, DO
St. Jude Children's Research Hospital
Alberto Pappo, MD
St. Jude Children's Research Hospital
Gregory Armstrong, MD
St. Jude Children's Research Hospital
Patrick Wen, MD
Dana-Farber Cancer Institute
Minesh Mehta, MD
Florida International University Herbert Wertheim College of Medicine
David Reardon, MD
Dana-Farber Cancer Institute
Timothy Cloughesy, MD
Ronald Reagan UCLA Medical Center